SCHEMBL29317904

SCHEMBL29317904

CNC(=O)c1cc2c(Oc3cc(OC)cc(-n4cccn4)c3)ccnc2cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 5/20 0.54
▸ KDR P35968 8/20 0.54
▸ MET P08581 5/20 0.54
▸ AURKB Q96GD4 4/20 0.54
▸ AURKA O14965 3/20 0.54
▸ TEK Q02763 3/20 0.54
▸ LCK P06239 2/20 0.54
▸ MERTK Q12866 1/20 0.48
▸ PDGFRA P16234 4/20 0.46
▸ PDGFRB P09619 2/20 0.46
▸ KIT P10721 1/20 0.45
▸ RET P07949 3/20 0.45
▸ DDR2 Q16832 2/20 0.45
▸ FGFR1 P11362 2/20 0.45
▸ FLT1 P17948 2/20 0.45
▸ FGFR2 P21802 2/20 0.45
▸ FLT4 P35916 2/20 0.45
▸ PDXK O00764 1/20 0.45
▸ RIPK2 O43353 1/20 0.45
▸ LYN P07948 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051321 1.00 AXL (0.54) AXLKDRMETAURKBAURKA
SCHEMBL29317875 0.91 AXL (0.53) AXLKDRMETAURKBAURKA
SCHEMBL30050356 0.89 KDR (0.59) AXLKDRMETAURKBAURKA
SCHEMBL29317871 0.89 KDR (0.59) AXLKDRMETAURKBAURKA
SCHEMBL29186539 0.86 MET (0.50) AXLKDRMETAURKBAURKA
SCHEMBL30050388 0.86 MET (0.50) AXLKDRMETAURKBAURKA
SCHEMBL29317863 0.85 PDGFRA (0.56) PDGFRAPDGFRBFGFR2
SCHEMBL30051021 0.85 PDGFRA (0.56) PDGFRAPDGFRBFGFR2
SCHEMBL29317818 0.85 KDR (0.61) AXLKDRMETAURKBAURKA
SCHEMBL30050696 0.85 KDR (0.61) AXLKDRMETAURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 — — US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, CPT1A, OAT AXL 4879/4885KDR 4885/4885MET 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback